Zucara Therapeutics

Risk score

57

Headquarters

Flag of CanadaCanada

Zucara Therapeutics is in the process of developing the initial daily remedy to prevent low blood sugar (hypoglycemia) in individuals with diabetes. This preclinical innovation is focused on regulating a hormone known as somatostatin in the pancreas, which is not properly controlled in Type 1 diabetes. It has shown potential to specifically inhibit somatostatin type 2 receptors in the pancreas, thus averting hypoglycemia and reinstating natural blood glucose levels.